Hyperuricemia
Conditions
Interventions
hydroxychloroquine:hydroxychloroquine+life style management
placebo:life style management
Sponsors
Huadong Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1) Understand the whole process of the experiment and sign the informed consent; (2) The age ranged from 18 to 75 years old, male; (3) After stopping high purine and high protein diet for 2 weeks or antiuricemic drugs for 2 weeks, fasting blood uric acid was measured twice on different days: 420 umol/L (7Mg / dl) 540 umol/L (9mg/dl); (4) Asymptomatic hyperuricemia patients had no gout arthritis, gout stone, uric acid kidney stone and other gout clinical manifestations, and the course of disease was within 2 years; (5) Be able to understand and cooperate with relevant research contents.
Exclusion criteria
Exclusion criteria: (1) Patients with secondary hyperuricemia, such as leukemia, myeloma, renal failure, polycystic kidney disease, some endocrine diseases, some drugs such as diuretics, aspirin, antituberculosis drugs, etc; (2) Combined with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases; (3) Patients with acute or chronic infectious diseases; (4) Allergic constitution or allergic to the components of this drug, weak constitution; (5) Those who do not meet the inclusion criteria, fail to use drugs and complete the treatment according to the regulations, cannot judge the curative effect or incomplete data, which affects the judgment of efficacy or safety; (6) Patients with malignant tumor; (7) ECG examination showed serious arrhythmia; (8) Mental illness, alcohol abuse, drug or other substance abusers; (9) The mean sitting systolic pressure (SBP) >=140mmHg, DBP >=90mmHg, or SBP >=160mmhg and DBP >=100mmhg during the observation period; (10) Heart failure with reduced ejection fraction (hfref) was clinically diagnosed and had persistent clinical symptoms; (11) Stroke, transient ischemic attack, acute coronary syndrome or deterioration of heart failure requiring hospitalization occurred in the first half of the observation period; (12) Congenital or acquired solitary kidney; (13) Three months before randomization, they participated in other clinical trials; (14) Subjects with WBC < 3.0x10^9/L, anemia (hemoglobin < 80 g/L), platelets < 80x10^9/L, or other blood system diseases; (15) Patients with history of chronic diarrhea or peptic ulcer in recent 1 year; (16) Patients with retinopathy or keratopathy; (17) There were patients with delayed porphyria and psoriasis; (18) Patients with rare genetic diseases such as galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption; (19) Any other condition or treatment that may result in the patient not being suitable for the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urinary urate excretion;serum urate;hydroxychloroquine metabolite;Urinary exosome proteomics; | — |
Countries
China
Contacts
Public ContactXiao Jing
Huadong Hospital Affiliated to Fudan University
Outcome results
None listed